Retrophin is a biopharmaceutical company that is based in San Diego, California. The company’s leading pipeline assets are fosmetpantotenate (RE-024), is a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease. Its marketed products include Chenodal, Cholbam and Thiola. Retrophin was founded in 2011.